By Katherine Hamilton
Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.
Alset approved a stock buyback up to $1 million. It said it doesn't think its stock price reflects its value. Shares rose 7% to 99 cents after the market closed Monday.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
June 23, 2025 19:29 ET (23:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.